For instance, it's been reported that METTL3 partners with YTHDF1 to boost hepatocellular carcinoma progression,34 triggers the PI3K/AKT signaling pathway to enhance prostate cancer growth,35 and plays roles in chemoresistance across various cancers like oral cancer,36 acute myeloid leukemia,37 and more. Here, AKT1 is linked to prostate carcinoma.